All S1PR modulators approved for the treatment of MS, including siponimod and fingolimod, are known to inhibit the egress of lymphocytes from lymphoid organs, especially the exit of activated T cells from lymph nodes into blood, an effect attributed to a functional antagonism on the S1PR1 of lymphocytes [15]. The gene discussed is S1PR1; the disease is myeloid sarcoma.